Table Graph
   

anti-inflammatory therapies - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.96 [0.86, 1.07]< 135%9 studies (8/1)76.9 %moderateserious moderatecrucial-
death or transfer to ICU 0.83 [0.35, 1.95]< 10%1 study (1/-)66.5 %NAnot evaluable crucial-
deaths 0.81 [0.69, 0.94]< 163%18 studies (12/6)99.7 %lowcritical highcrucial-
deaths (time to event analysis only) 0.46 [0.21, 1.03]< 183%4 studies (2/2)97.1 %lownot evaluable highcrucial-
clinical deterioration 0.34 [0.08, 1.43]< 177%5 studies (3/2)92.9 %lowserious highimportant-
clinical improvement 11.50 [2.57, 51.44]> 10%2 studies (1/1)99.9 %lownot evaluable highimportant-
clinical improvement (14-day) 10.27 [1.17, 90.18]> 10%1 study (1/-)98.2 %NAnot evaluable important-
clinical improvement (28-day) 3.52 [1.28, 9.72]> 10%2 studies (1/1)99.2 %NAnot evaluable important-
clinical improvement (7-day) 6.72 [1.50, 30.07]> 10%1 study (1/-)99.4 %NAnot evaluable important-
death or ventilation 0.94 [0.78, 1.15]< 170%2 studies (2/-)71.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.52 [0.92, 2.52]> 181%4 studies (2/2)95.0 %lownot evaluable highimportant-
mechanical ventilation 0.88 [0.72, 1.07]< 155%7 studies (5/2)90.3 %lowserious highimportant-
radiologic improvement (14-day) 2.87 [1.56, 5.28]> 10%1 study (1/-)100.0 %NAnot evaluable important-
ICU admission 1.00 [0.87, 1.16]< 10%4 studies (3/1)48.0 %NAnot evaluable non important-
recovery 3.46 [1.05, 11.35]> 10%1 study (1/-)97.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.19 [0.04, 0.84]< 10%3 studies (3/-)98.6 %some concernnot evaluable moderateimportant-
adverse events 1.24 [0.75, 2.04]< 15%5 studies (5/-)20.5 %lownot evaluable highnon important-
cardiovascular or renal events 1.87 [1.25, 2.80]< 10%1 study (-/1)0.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons